Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have a body mass index (BMI) of ≤38.0 kg/m\^2~* Have a clinical diagnosis of Type 2 diabetes mellitus~* Have a glycated hemoglobin (HbA1C) at screening ≤9.0%; fasting plasma glucose should not exceed 300 mg/dL (16.8 mmol/L)~* Judged to be in good health~Exclusion Criteria:~* Have a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study~* Have a history of stroke, chronic seizures, major neurological disorder, clinically significant endocrine, cardiovascular, hematological, hepatic, renal, respiratory, or genitourinary abnormalities or diseases~* Have untreated hypertension with blood pressure of \>160/95 mmHg~* Have a history of neoplastic disease within the past 5 years~* Have a history of hypersensitivity to OXM, liraglutide, insulin or Haemaccel®~* Unable or unwilling to comply with restrictions around concomitant medications~* Consume excessive amounts of alcohol, coffee, tea, cola, or other caffeinated beverages daily~* Have had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks~* Have a history of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food~* Currently a regular user (including use of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 3 months~* Are unwilling or unable to consume the standardized meals during the study and/or is on a carbohydrate restricted diet (i.e., a diet \<100 grams per day of carbohydrate)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- OXM → Lg-0.6 → Pbo → Lg-1.2 (Type: EXPERIMENTAL): Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period
- Lg-0.6 → Pbo → OXM → Pbo (Type: EXPERIMENTAL): Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period
- Pbo → OXM → Lg-0.6 → Pbo (Type: EXPERIMENTAL): Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
- Lg-0.6 → OXM → Pbo → Lg-1.2 (Type: EXPERIMENTAL): Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period
- OXM → Pbo → Lg-0.6 → Pbo (Type: EXPERIMENTAL): Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
- Pbo → Lg-0.6 → OXM → Lg-1.2 (Type: EXPERIMENTAL): Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period

Based on this trial design, predict the completion outcome and termination type (if applicable).